Nuvalent, Inc.

Pharmaceutical Preparations·CAMBRIDGE, MA·FY end 12/31·CIK 1861560

CEO Pay Ratio

21:1

CEO Total Comp

—

Median Employee

—

Revenue

—

FY 2025

Net Income

-$425.4M

FY 2025

Free Cash Flow

—

FY 2025

Net Margin

—

Insider Net (180d)

0 buys / 0 sales

CEO Pay Accountability

CEO comp as % of net income

—

Not enough data to compute.

CEO comp as % of buybacks

—

No buyback data for the most recent fiscal year.

5-year history · USD

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	Trend
Revenue	—	—	—	—	—	—
Gross Profit	—	—	—	—	—	—
Operating Income	-$414.3M	-$280.4M	-$149.5M	-$86.1M	-$45.8M
Net Income	-$425.4M	-$260.8M	-$126.2M	-$81.9M	-$46.3M
Operating CF	-$275.2M	-$185.1M	-$99.7M	-$65.0M	-$40.0M
Capex	—	—	—	—	—	—
Free Cash Flow	—	—	—	—	—	—
Buybacks	—	—	—	—	—	—
Dividends	—	—	—	—	—	—

Gross Margin	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—
FCF Margin	—	—	—	—	—	—
R&D / Revenue	—	—	—	—	—	—
Effective Tax	-0.1%	-0.3%	—	—	—
Debt / Equity	—	—	—	—	—	—
Buybacks / FCF	—	—	—	—	—	—

FY 2025

Executive	Salary	Stock	Options	Bonus / Inc.	Other	Total
James R. PorterPh.D.	$652.1K	$4.4M	$5.9M	$469.5K	$21.5K	$11.4M
Christopher D. TurnerM.D.	$520.1K	$1.5M	$2.0M	$280.9K	$21.5K	$4.2M
Alexandra BalcomMBA, CPA	$475.5K	$1.5M	$2.0M	$256.8K	$21.5K	$4.2M
Darlene NociALM	$467.4K	$1.5M	$2.0M	$252.4K	$21.5K	$4.2M
Deborah MillerPh.D., J.D.	$467.0K	$1.5M	$2.0M	$252.2K	$21.5K	$4.2M